Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APERNAVEC in Secondary Lymphedema
NCT07793656Phase 2Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in secondary lymphedema, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Safety profile of APERNAVEC vector injection at 1 month. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
secondary lymphedema
Beyond the preview
Go deeper on NCT07793656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793656.